In breast cancer, both having high levels of the proinflammatory signaling molecule CCL2 and having macrophages, a type of immune cell, infiltrate the tumor bodes poorly for the patients. A new study showed the link between those two observations, and suggested that targeting CCL2 signaling might be a way to treat metastatic breast cancer.